Fig. 1From: Pneumocystis pneumonia in patients with rheumatic diseases receiving prolonged, non-high-dose steroids—clinical implication of primary prophylaxis using trimethoprim–sulfamethoxazoleThe 1-year incidence rates of pneumocystis pneumonia in treatment episodes with various ranges of steroid doses. Notably, the incidence was considerably higher for daily doses of steroids ≥ 15 mg of prednisone or equivalent. Error bar indicates the upper margin of the 95% confidence interval of the incidence rateBack to article page